All Cancer articles
-
PodcastDrugging the ‘undruggable’ cancer proteins & conserving the Bayeux Tapestry
How did molecular glues help crack one of cancer’s toughest targets? And we explore the chemistry behind the investigation and conservation of the Bayeux Tapestry.
-
PodcastAdvances in CAR-T cancer therapy & carbon materials’ hidden defects
What does recent success with bladder tumours mean for solid cancer treatment? And we discuss why scientists are rethinking how they assign peaks in spectra of carbon-based materials.
-
WebinarBoron: in search of the real fifth element
What makes boron so extraordinary? Find out on 21 October with author Stephen Mansell
-
ResearchStep forward for CAR-T therapy as it shows promise in solid bladder tumours
Animal tests show targeting bladder cancer specific protein can treat tumours and could cut need for surgery
-
BusinessJ&J proposes $5.5 billion settlement deal for talc cancer lawsuits
Deal would resolve 76,000 cases of women claiming talc caused ovarian cancer
-
OpinionGSK agrees $10 billion deal for Nuvalent cancer drugs
Deal includes two late-stage molecules to augment GSK’s renewed cancer therapy pipeline
-
Business‘Basic research is needed more than anything else’
Christian Hackenberger, co-founder of Tubulis, is excited that his team’s initial research is now creating clinical impact
-
BusinessUS backs Bayer–Monsanto with glyphosate decision
Solicitor general says federal rules override state laws on cancer warnings
-
BusinessJ&J now faces talc cancer claims in the UK
Alongside nearly 70,000 US lawsuits, over 3000 claimants have filed joint UK legal action
-
WebinarDeveloping a CITK protein degrader using the QuicTPD™ platform
Learn about the latest technology to accelerate the design of cancer treatments
-
BusinessTitanium dioxide loses EU carcinogen label after court ruling
EU products no longer have to carry warnings about cancer risk from inhalation
-
WebinarIon suppression correction and normalisation in metabolomics
Join us to learn new ways to improve data consistency with mass spectrometry
-
BusinessSanofi to buy Blueprint Medicines for over $9 billion
Blueprint has one approved drug and enhances Sanofi’s immunology portfolio
-
ResearchNanocomplex becomes a master of shape-shifting to target tumour cells
Switching from nanofibres in the blood to virus-like particles in a tumour environment brings drugs to where they are needed
-
OpinionThe women-led health projects doing things differently
Innovative approaches to awareness and participation
-
BusinessMerck KGaA to buy cancer specialist SpringWorks
$3.9 billion deal boosts Merck’s pipeline as it faces patent expiries
-
BusinessJ&J’s third talc bankruptcy settlement attempt denied
Company says it will return to courts to fight talc cancer claims
-
BusinessBayer ordered to pay more than $2 billion to US cancer victim
Jury decided glyphosate-based Roundup herbicide caused cancer, but company will appeal
-
OpinionGetting into the weeds of the glyphosate debate
Assessments of the risk posed by the controversial herbicide depend on how the evidence is weighed
-
BusinessUS government moves to block J&J talc bankruptcy resolution
Firm’s third attempt to shift claims to a subsidiary had gained significant support